DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

12-14-98

DEC 14 1998

/5

Re: Omincef Oral Suspension®
    Docket No. 98E-0840

Stephen G. Kunin
Deputy Assistant Commissioner for
  Patent Policy and Projects
U.S. Patent and Trademark Office
Box Pat. Ext.
Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Mr. Kunin:

This is in regard to the application for patent term extension for U.S. Patent No. 4,935,507 filed by Warner-Lambert Company under 35 U.S.C. § 156. The human drug product claimed by the patent is Omincef Oral Suspension® (cefdinir), which was assigned New Drug Application (NDA) No. 50-749.

A review of the Food and Drug Administration's official records indicates that this product was subject to a regulatory review period before its commercial marketing or use, as required under 35 U.S.C. § 156(a)(4). Our records also indicate that it represents the first permitted commercial marketing or use of the product, as defined under 35 U.S.C. § 156(f)(1), and interpreted by the courts in Glaxo Operations UK Ltd. v. Quigg, 706 F. Supp. 1224 (E.D. Va. 1989), aff'd, 894 F. 2d 392 (Fed. Cir. 1990).

The NDA was approved on December 4, 1997, which makes the submission of the patent term extension application on January 27, 1998, timely within the meaning of 35 U.S.C. § 156(d)(1).

Should you conclude that the subject patent is eligible for patent term extension, please advise us accordingly. As required by 35 U.S.C. § 156(d)(2)(A) we will then determine the applicable regulatory review period, publish the determination in the Federal Register, and notify you of our determination.

Please let me know if we can be of further assistance.

Sincerely yours,

Ronald L. Wilson, Director
Health Assessment Policy Staff
Office of Health Affairs

cc: Charles W. Ashbrook
      Warner-Lambert Company
      Park-Davis Pharmaceutical Research Div.
      2800 Plymouth Road
      Ann Arbor, MI 48105